EE05221B1 - HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod - Google Patents

HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod

Info

Publication number
EE05221B1
EE05221B1 EEP200200411A EEP200200411A EE05221B1 EE 05221 B1 EE05221 B1 EE 05221B1 EE P200200411 A EEP200200411 A EE P200200411A EE P200200411 A EEP200200411 A EE P200200411A EE 05221 B1 EE05221 B1 EE 05221B1
Authority
EE
Estonia
Prior art keywords
hmg
preparing
compositions containing
inorganic salt
coa reductase
Prior art date
Application number
EEP200200411A
Other languages
English (en)
Estonian (et)
Inventor
Richard Creekmore Joseph
Alfred Wiggins Norman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05221(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to EEP200900047A priority Critical patent/EE05586B1/xx
Publication of EE200200411A publication Critical patent/EE200200411A/xx
Publication of EE05221B1 publication Critical patent/EE05221B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200411A 2000-01-26 2000-08-04 HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod EE05221B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
PCT/GB2000/003017 WO2001054669A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Publications (2)

Publication Number Publication Date
EE200200411A EE200200411A (et) 2003-12-15
EE05221B1 true EE05221B1 (et) 2009-10-15

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
EEP200200411A EE05221B1 (et) 2000-01-26 2000-08-04 HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod
EEP200200052A EE04990B1 (et) 2000-01-26 2000-08-04 HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Family Applications After (2)

Application Number Title Priority Date Filing Date
EEP200200052A EE04990B1 (et) 2000-01-26 2000-08-04 HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Country Status (48)

Country Link
US (2) US6316460B1 (cs)
EP (6) EP1251831A1 (cs)
JP (3) JP4800467B2 (cs)
KR (3) KR100388713B1 (cs)
CN (3) CN100528161C (cs)
AP (2) AP1879A (cs)
AR (3) AR023624A1 (cs)
AT (3) AT412062B (cs)
AU (5) AU738074B2 (cs)
BE (2) BE1013414A5 (cs)
BG (4) BG65234B1 (cs)
BR (2) BR0003364A (cs)
CA (3) CA2315141C (cs)
CH (2) CH691347A5 (cs)
CL (1) CL2007001807A1 (cs)
CR (3) CR6568A (cs)
CZ (3) CZ298411B6 (cs)
DE (3) DE60001371T2 (cs)
DK (3) DK178242B1 (cs)
EE (3) EE05221B1 (cs)
ES (2) ES2171123B1 (cs)
FI (3) FI121365B (cs)
FR (2) FR2804025B1 (cs)
GB (3) GB0001621D0 (cs)
HK (4) HK1047052A1 (cs)
HR (3) HRP20020632B1 (cs)
HU (2) HUP0003111A3 (cs)
IL (4) IL147870A (cs)
IS (3) IS1940B (cs)
IT (2) ITTO20000780A1 (cs)
ME (4) MEP33808A (cs)
MY (2) MY122707A (cs)
NL (2) NL1015859C2 (cs)
NO (4) NO312434B1 (cs)
NZ (2) NZ531474A (cs)
PL (2) PL341855A1 (cs)
PT (3) PT1223918E (cs)
RS (1) RS50201B (cs)
RU (2) RU2264210C2 (cs)
SE (2) SE523481C2 (cs)
SI (1) SI1223918T1 (cs)
SK (2) SK11792000A3 (cs)
TR (3) TR200701171T2 (cs)
TW (2) TW553749B (cs)
UA (2) UA51853C2 (cs)
WO (2) WO2001054669A1 (cs)
YU (1) YU52902A (cs)
ZA (2) ZA200003997B (cs)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6558659B2 (en) † 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
JPWO2004016262A1 (ja) * 2002-08-12 2005-12-02 協和醗酵工業株式会社 アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
EP1562912A2 (en) * 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
PT3395338T (pt) * 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
PT1689723E (pt) * 2003-12-02 2011-07-06 Teva Pharma Padrão referência para a caracterização de rosuvastatina
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
TW201240679A (en) * 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
EP2455067B1 (en) * 2004-05-04 2016-10-12 Innophos, Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
CA2680693A1 (en) * 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
RU2303980C2 (ru) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Лекарственная форма с антиагрегационным действием и способ ее изготовления
KR20080033410A (ko) * 2005-08-04 2008-04-16 트렌스폼 파마수티컬스 인코퍼레이티드 페노피브레이트 및 스타틴을 포함하는 신규한 제제 및 관련치료방법
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
BRPI0615898B8 (pt) 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
ES2375643T3 (es) * 2005-10-31 2012-03-02 Kowa Company, Ltd. Preparación farmacéutica que presenta excelente fotoestabilidad.
US20090093499A1 (en) * 2005-12-20 2009-04-09 Lek Pharmaceuticals D.D. Pharmaceutical composition
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en) * 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008044243A2 (en) * 2006-10-09 2008-04-17 Manne Satyanarayana Reddy Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
US20110003837A1 (en) * 2008-01-30 2011-01-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
JP2012502883A (ja) * 2008-06-13 2012-02-02 グラクソ グループ リミテッド 医薬製剤
PL2309992T3 (pl) * 2008-06-27 2018-05-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Kompozycja farmaceutyczna zawierająca statynę
JP2011525901A (ja) * 2008-06-27 2011-09-29 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ ロスバスタチンカルシウム含有医薬組成物
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (en) 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
AU2012260605B2 (en) 2011-05-20 2015-02-19 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
DK2851075T3 (da) * 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
EP2977048A4 (en) * 2013-03-12 2017-04-26 LG Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3219318A4 (en) * 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
ES2963058T3 (es) 2015-12-08 2024-03-25 Lyndra Therapeutics Inc Configuraciones geométricas para sistemas de residencia gástrica
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
WO2017205844A2 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
AU3214689A (en) * 1988-10-06 1990-05-01 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DE69104453T2 (de) 1990-09-13 1995-03-16 Akzo Nv Stabilisierte feste chemische Zusammensetzungen.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
ATE178794T1 (de) 1993-01-19 1999-04-15 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
SK282991B6 (sk) * 1995-12-22 2003-01-09 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozícia na báze kyseliny (E)- 3,5-dihydroxy-7-[4'-4''-fluórfenyl-2'-cyklopropylchinolin-3'yl]- 6-hepténovej
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
HUP0102260A3 (en) 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
EP2133070A1 (en) 2009-12-16
AT412062B (de) 2004-09-27
TR200201888T2 (tr) 2002-11-21
KR20010077840A (ko) 2001-08-20
FI20001750A0 (fi) 2000-08-04
IL150513A (en) 2012-12-31
HK1040936B (zh) 2010-06-11
CN101028268A (zh) 2007-09-05
TR200701171T2 (tr) 2007-04-24
AU6580000A (en) 2001-08-07
HRP20080525A2 (en) 2008-12-31
DE10038108A1 (de) 2001-08-02
PT102503A (pt) 2000-12-29
FR2795324B1 (fr) 2002-05-17
HK1047052A1 (zh) 2003-02-07
AP1879A (en) 2008-08-14
PT102504A (pt) 2001-07-31
FI20105657L (fi) 2010-06-10
IS1940B (is) 2004-07-16
IS6480A (is) 2002-07-23
EE200200052A (et) 2003-04-15
GB2358582A (en) 2001-08-01
HU222578B1 (hu) 2003-08-28
EP2266540A1 (en) 2010-12-29
HRP20020097B1 (hr) 2010-12-31
BE1013414A5 (fr) 2001-12-04
PT102503B (pt) 2004-02-27
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
AU2005202392B2 (en) 2008-11-20
US6548513B1 (en) 2003-04-15
HK1048950A1 (zh) 2003-04-25
ZA200003997B (en) 2000-08-14
CL2007001807A1 (es) 2008-01-18
BE1013413A3 (fr) 2001-12-04
FR2804025A1 (fr) 2001-07-27
MY122707A (en) 2006-04-29
DE60001371D1 (de) 2003-03-13
KR20000072135A (ko) 2000-12-05
IL147870A (en) 2003-10-31
HK1036934A1 (en) 2002-01-25
SI1223918T1 (en) 2003-06-30
GB0001621D0 (en) 2000-03-15
HU0003110D0 (en) 2000-10-28
PL196808B1 (pl) 2008-02-29
ES2155043B1 (es) 2001-12-01
CN1319396A (zh) 2001-10-31
JP4800467B2 (ja) 2011-10-26
ITTO20000780A1 (it) 2000-11-04
MEP33708A (hr) 2010-10-10
NO20003968D0 (no) 2000-08-04
BG65234B1 (bg) 2007-09-28
CN100528161C (zh) 2009-08-19
TWI228050B (en) 2005-02-21
IL147870A0 (en) 2002-08-14
ATE232088T1 (de) 2003-02-15
AR060248A2 (es) 2008-06-04
AU5184200A (en) 2001-08-02
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
HUP0003111A3 (en) 2003-03-28
HUP0003110A2 (hu) 2001-05-28
IL150513A0 (en) 2003-02-12
ME00191B (me) 2010-10-10
RU2002122752A (ru) 2004-03-10
HUP0003111A2 (hu) 2002-02-28
SE0002827D0 (sv) 2000-08-04
CR6687A (es) 2005-07-18
TW553749B (en) 2003-09-21
SE523471C2 (sv) 2004-04-20
RS50201B (sr) 2009-07-15
RU2264210C2 (ru) 2005-11-20
IS6254A (is) 2002-01-29
DE10038110A1 (de) 2001-08-23
AU5184100A (en) 2001-08-02
CA2639407A1 (en) 2001-07-26
AU738074B2 (en) 2001-09-06
BG106926A (bg) 2003-04-30
NL1015859C2 (nl) 2001-10-16
EE04990B1 (et) 2008-04-15
CZ20002884A3 (cs) 2001-09-12
EP2018853A1 (en) 2009-01-28
YU52902A (sh) 2006-01-16
HRP20020632A2 (en) 2004-12-31
EP1251831A1 (en) 2002-10-30
SK11792000A3 (sk) 2001-12-03
HUP0003110A3 (en) 2003-02-28
AU2005202392A1 (en) 2005-06-30
BG66168B1 (bg) 2011-10-31
NL1015858C2 (nl) 2001-07-27
AU781269B2 (en) 2005-05-12
FI20001750L (fi) 2001-07-27
FR2804025B1 (fr) 2002-08-23
ATA13602000A (de) 2004-02-15
SK11782000A3 (sk) 2001-12-03
EP1223918A1 (en) 2002-07-24
GB2358583B (en) 2002-02-06
NL1015859A1 (nl) 2001-07-27
AT412063B (de) 2004-09-27
PL341853A1 (en) 2001-01-29
ATA13612000A (de) 2004-02-15
NO312434B1 (no) 2002-05-13
KR20030036492A (ko) 2003-05-09
AP1449A (en) 2005-07-28
AR023624A1 (es) 2002-09-04
NO20071303L (no) 2001-07-27
DK178242B1 (da) 2015-09-28
JP3267960B2 (ja) 2002-03-25
AU2005202392C1 (en) 2016-06-02
NO327675B1 (no) 2009-09-07
JP4800988B2 (ja) 2011-10-26
DK1223918T3 (da) 2003-04-28
SK283872B6 (sk) 2004-03-02
WO2001054669A1 (en) 2001-08-02
FI20001749A0 (fi) 2000-08-04
CA2639407C (en) 2011-09-13
FR2795324A1 (fr) 2000-12-29
EE200900047A (et) 2011-04-15
DK200001170A (da) 2001-01-27
MY123650A (en) 2006-05-31
ITTO20000779A1 (it) 2002-02-04
CZ298411B6 (cs) 2007-09-26
ITTO20000779A0 (it) 2000-08-04
JP2001206847A (ja) 2001-07-31
JP2007182452A (ja) 2007-07-19
CA2313783A1 (en) 2000-10-16
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
EP2774609A1 (en) 2014-09-10
CA2313783C (en) 2002-03-12
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
MEP33808A (hr) 2010-10-10
RU2206324C1 (ru) 2003-06-20
CZ290167B6 (cs) 2002-06-12
CH691347A5 (de) 2001-07-13
SE0002826D0 (sv) 2000-08-04
GB0019028D0 (en) 2000-09-27
BG110353A (en) 2009-09-30
DK200001171A (da) 2001-07-27
NZ519774A (en) 2004-04-30
BR0003365A (pt) 2001-09-18
NO20003967D0 (no) 2000-08-04
UA77156C2 (en) 2006-11-15
NO327554B1 (no) 2009-08-10
ES2171123A1 (es) 2002-08-16
AU781269C (en) 2006-11-30
IS2805B (is) 2012-09-15
EE200200411A (et) 2003-12-15
CR6568A (es) 2004-03-05
AP2002002409A0 (en) 2002-03-31
NO20003967L (no) 2001-07-27
NO20003968L (no) 2001-07-27
KR100388713B1 (ko) 2003-06-25
DE10038110B4 (de) 2006-06-29
JP2001206877A (ja) 2001-07-31
NO2010005I1 (no) 2010-05-03
AP2002002591A0 (en) 2002-09-30
TR200200270T2 (tr) 2002-06-21
GB2358582B (en) 2004-09-29
PL341855A1 (en) 2001-07-30
IS8620A (is) 2007-03-07
BG106393A (en) 2002-07-31
EE05586B1 (et) 2012-10-15
ME00202B (me) 2010-10-10
CA2315141C (en) 2009-08-18
SE523481C2 (sv) 2004-04-20
EP1223918B1 (en) 2003-02-05
AU2000264559A1 (en) 2001-08-07
PT1223918E (pt) 2003-06-30
CZ20002883A3 (cs) 2000-10-11
CA2315141A1 (en) 2001-07-26
HRP20020632B1 (en) 2010-12-31
IL187416A0 (en) 2008-02-09
UA51853C2 (uk) 2002-12-16
HK1036935A1 (en) 2002-01-25
HK1040936A1 (zh) 2002-06-28
BR0003364A (pt) 2001-09-18
CZ299105B6 (cs) 2008-04-23
FI121365B (fi) 2010-10-29
HK1200368A1 (en) 2015-08-07
ES2171123B1 (es) 2003-11-16
YU5202A (sh) 2004-12-31
NZ531474A (en) 2007-04-27
CR10114A (es) 2008-08-21
CH700184B1 (de) 2010-07-15
SE0002826L (sv) 2001-07-27
BG66159B1 (bg) 2011-09-30
AR025055A1 (es) 2002-11-06
FI111806B (fi) 2003-09-30
CN1149997C (zh) 2004-05-19
DE60001371T2 (de) 2004-01-22
GB0019029D0 (en) 2000-09-27
FI20001749L (fi) 2001-07-27
HU0003111D0 (en) 2000-10-28
KR100698333B1 (ko) 2007-03-23
CN1282581A (zh) 2001-02-07

Similar Documents

Publication Publication Date Title
EE05221B1 (et) HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod
EE200300054A (et) Kinaasi inhibiitoritena toimivad bitsüklopürasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
HUS1200031I1 (hu) Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
IL198996A (en) Use of a tyrosine kinase inhibitor for its preparation as a medicinal preparation
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
NO20032425D0 (no) Nye krystallformer av atorvastatin-hemi-kalsium og fremgangsmåter for deresfremstilling, samt nye fremgangsmåter for fremstilling av andreformer
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
HUP0303624A3 (en) N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds
IL152872A0 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
NO923089D0 (no) Tetrahydroindazol, tetrahydrocyklopentapyrazol og heksahydrocykloheptapyrazol forbindelser og deres anvendelse som hmg-coa reduktase-hemmere
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
FI20010849L (fi) Täyteaine ja menetelmä sen valmistamiseksi
NO20043919L (no) Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
AU2001293869A1 (en) Butenolide and pentenolide derivatives as kinase inhibitors

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231